These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28062216)

  • 1. Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.
    Majzner RG; Mogri H; Varadhan R; Brown P; Cooke KR; Bolaños-Meade J; Swinnen L; Kanakry J; Luznik L; Jones RJ; Fuchs E; Ambinder R; Kasamon Y; Symons HJ
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):612-617. PubMed ID: 28062216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.
    Kanakry JA; Kasamon YL; Bolaños-Meade J; Borrello IM; Brodsky RA; Fuchs EJ; Ghosh N; Gladstone DE; Gocke CD; Huff CA; Kanakry CG; Luznik L; Matsui W; Mogri HJ; Swinnen LJ; Symons HJ; Jones RJ; Ambinder RF
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1514-7. PubMed ID: 23871780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Martínez C; Gayoso J; Canals C; Finel H; Peggs K; Dominietto A; Castagna L; Afanasyev B; Robinson S; Blaise D; Corradini P; Itälä-Remes M; Bermúdez A; Forcade E; Russo D; Potter M; McQuaker G; Yakoub-Agha I; Scheid C; Bloor A; Montoto S; Dreger P; Sureda A;
    J Clin Oncol; 2017 Oct; 35(30):3425-3432. PubMed ID: 28846465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study.
    Berger M; Lanino E; Cesaro S; Zecca M; Vassallo E; Faraci M; De Bortoli M; Barat V; Prete A; Fagioli F
    Biol Blood Marrow Transplant; 2016 May; 22(5):902-9. PubMed ID: 26860636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond post-transplantation cyclophosphamide in younger children.
    Jaiswal SR; Chakrabarti A; Chatterjee S; Ray K; Chakrabarti S
    Pediatr Transplant; 2016 Aug; 20(5):675-82. PubMed ID: 27217372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation.
    Lynch BA; Vasef MA; Comito M; Gilman AL; Lee N; Ritchie J; Rumelhart S; Holida M; Goldman F
    Bone Marrow Transplant; 2003 Sep; 32(5):527-33. PubMed ID: 12942101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.